Bill Text: FL S1738 | 2021 | Regular Session | Introduced
Bill Title: Controlled Substances
Spectrum: Partisan Bill (Republican 1-0)
Status: (Failed) 2021-04-30 - Died in Health Policy [S1738 Detail]
Download: Florida-2021-S1738-Introduced.html
Florida Senate - 2021 SB 1738
By Senator Brodeur
9-01008B-21 20211738__
1 A bill to be entitled
2 An act relating to controlled substances; amending s.
3 893.03, F.S.; excluding from Schedule I cannabis if it
4 is contained within a pharmaceutical product approved
5 by the United States Food and Drug Administration;
6 providing an effective date.
7
8 Be It Enacted by the Legislature of the State of Florida:
9
10 Section 1. Paragraph (c) of subsection (1) of section
11 893.03, Florida Statutes, is amended to read:
12 893.03 Standards and schedules.—The substances enumerated
13 in this section are controlled by this chapter. The controlled
14 substances listed or to be listed in Schedules I, II, III, IV,
15 and V are included by whatever official, common, usual,
16 chemical, trade name, or class designated. The provisions of
17 this section shall not be construed to include within any of the
18 schedules contained in this section any excluded drugs listed
19 within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
20 Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
21 Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
22 Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
23 Anabolic Steroid Products.”
24 (1) SCHEDULE I.—A substance in Schedule I has a high
25 potential for abuse and has no currently accepted medical use in
26 treatment in the United States and in its use under medical
27 supervision does not meet accepted safety standards. The
28 following substances are controlled in Schedule I:
29 (c) Unless specifically excepted or unless listed in
30 another schedule, any material, compound, mixture, or
31 preparation that contains any quantity of the following
32 hallucinogenic substances or that contains any of their salts,
33 isomers, including optical, positional, or geometric isomers,
34 homologues, nitrogen-heterocyclic analogs, esters, ethers, and
35 salts of isomers, homologues, nitrogen-heterocyclic analogs,
36 esters, or ethers, if the existence of such salts, isomers, and
37 salts of isomers is possible within the specific chemical
38 designation or class description:
39 1. Alpha-Ethyltryptamine.
40 2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
41 oxazoline).
42 3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
43 4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
44 5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
45 6. Bufotenine.
46 7. Cannabis, except if it is contained within a
47 pharmaceutical product approved by the United States Food and
48 Drug Administration.
49 8. Cathinone.
50 9. DET (Diethyltryptamine).
51 10. 2,5-Dimethoxyamphetamine.
52 11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
53 12. DMT (Dimethyltryptamine).
54 13. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine
55 analog of phencyclidine).
56 14. JB-318 (N-Ethyl-3-piperidyl benzilate).
57 15. N-Ethylamphetamine.
58 16. Fenethylline.
59 17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
60 18. Ibogaine.
61 19. LSD (Lysergic acid diethylamide).
62 20. Mescaline.
63 21. Methcathinone.
64 22. 5-Methoxy-3,4-methylenedioxyamphetamine.
65 23. PMA (4-Methoxyamphetamine).
66 24. PMMA (4-Methoxymethamphetamine).
67 25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
68 26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
69 27. MDA (3,4-Methylenedioxyamphetamine).
70 28. JB-336 (N-Methyl-3-piperidyl benzilate).
71 29. N,N-Dimethylamphetamine.
72 30. Parahexyl.
73 31. Peyote.
74 32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
75 analog of phencyclidine).
76 33. Psilocybin.
77 34. Psilocyn.
78 35. Salvia divinorum, except for any drug product approved
79 by the United States Food and Drug Administration which contains
80 Salvia divinorum or its isomers, esters, ethers, salts, and
81 salts of isomers, esters, and ethers, if the existence of such
82 isomers, esters, ethers, and salts is possible within the
83 specific chemical designation.
84 36. Salvinorin A, except for any drug product approved by
85 the United States Food and Drug Administration which contains
86 Salvinorin A or its isomers, esters, ethers, salts, and salts of
87 isomers, esters, and ethers, if the existence of such isomers,
88 esters, ethers, and salts is possible within the specific
89 chemical designation.
90 37. Xylazine.
91 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
92 (Thiophene analog of phencyclidine).
93 39. 3,4,5-Trimethoxyamphetamine.
94 40. Methylone (3,4-Methylenedioxymethcathinone).
95 41. MDPV (3,4-Methylenedioxypyrovalerone).
96 42. Methylmethcathinone.
97 43. Methoxymethcathinone.
98 44. Fluoromethcathinone.
99 45. Methylethcathinone.
100 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
101 yl)phenol) and its dimethyloctyl (C8) homologue.
102 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
103 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
104 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
105 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
106 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
107 naphthoyl)indole).
108 51. BZP (Benzylpiperazine).
109 52. Fluorophenylpiperazine.
110 53. Methylphenylpiperazine.
111 54. Chlorophenylpiperazine.
112 55. Methoxyphenylpiperazine.
113 56. DBZP (1,4-Dibenzylpiperazine).
114 57. TFMPP (Trifluoromethylphenylpiperazine).
115 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
116 Methylenedioxy-N-methylbutanamine).
117 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
118 60. 5-Hydroxy-N-methyltryptamine.
119 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
120 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
121 63. Methyltryptamine.
122 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
123 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
124 66. Tyramine (4-Hydroxyphenethylamine).
125 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
126 68. DiPT (N,N-Diisopropyltryptamine).
127 69. DPT (N,N-Dipropyltryptamine).
128 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
129 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
130 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
131 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
132 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
133 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
134 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
135 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
136 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
137 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
138 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
139 81. Butylone (3,4-Methylenedioxy-alpha
140 methylaminobutyrophenone).
141 82. Ethcathinone.
142 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
143 84. Naphyrone (Naphthylpyrovalerone).
144 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
145 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
146 87. 3,4-Methylenedioxy-propiophenone.
147 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
148 89. 3,4-Methylenedioxy-propiophenone-2-oxime.
149 90. 3,4-Methylenedioxy-N-acetylcathinone.
150 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
151 92. 3,4-Methylenedioxy-N-acetylethcathinone.
152 93. Bromomethcathinone.
153 94. Buphedrone (alpha-Methylamino-butyrophenone).
154 95. Eutylone (3,4-Methylenedioxy-alpha
155 ethylaminobutyrophenone).
156 96. Dimethylcathinone.
157 97. Dimethylmethcathinone.
158 98. Pentylone (3,4-Methylenedioxy-alpha
159 methylaminovalerophenone).
160 99. MDPPP (3,4-Methylenedioxy-alpha
161 pyrrolidinopropiophenone).
162 100. MDPBP (3,4-Methylenedioxy-alpha
163 pyrrolidinobutyrophenone).
164 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
165 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
166 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
167 (Benocyclidine).
168 104. F-MABP (Fluoromethylaminobutyrophenone).
169 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
170 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
171 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
172 108. Me-EABP (Methylethylaminobutyrophenone).
173 109. Etizolam.
174 110. PPP (Pyrrolidinopropiophenone).
175 111. PBP (Pyrrolidinobutyrophenone).
176 112. PVP (Pyrrolidinovalerophenone) or
177 (Pyrrolidinopentiophenone).
178 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
179 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
180 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
181 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
182 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
183 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
184 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
185 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
186 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
187 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
188 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
189 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
190 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
191 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
192 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
193 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
194 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
195 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
196 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
197 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
198 ol).
199 131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
200 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
201 methanol).
202 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
203 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
204 1,4-dione).
205 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
206 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
207 undecanamide).
208 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
209 undecanamide).
210 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
211 methyloctan-2-yl)phenol).
212 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
213 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
214 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
215 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
216 methoxyphenylacetyl)indole).
217 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
218 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
219 naphthalenylmethanone).
220 142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
221 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
222 naphthalenylmethanone).
223 143. Pentedrone (alpha-Methylaminovalerophenone).
224 144. Fluoroamphetamine.
225 145. Fluoromethamphetamine.
226 146. Methoxetamine.
227 147. Methiopropamine.
228 148. Methylbuphedrone (Methyl-alpha
229 methylaminobutyrophenone).
230 149. APB ((2-Aminopropyl)benzofuran).
231 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
232 151. UR-144 (1-Pentyl-3-(2,2,3,3
233 tetramethylcyclopropanoyl)indole).
234 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
235 tetramethylcyclopropanoyl)indole).
236 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
237 tetramethylcyclopropanoyl)indole).
238 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
239 155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
240 iodobenzoyl)indole).
241 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
242 carboxamide).
243 157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
244 cyclohexylcarbamate).
245 158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
246 cyclohexyl ester).
247 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
248 benzoxazin-4-one).
249 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
250 161. 2C-H (2,5-Dimethoxyphenethylamine).
251 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
252 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
253 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
254 methoxybenzyl)]phenethylamine).
255 165. MDMA (3,4-Methylenedioxymethamphetamine).
256 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
257 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
258 carboxylate).
259 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
260 carboxylate).
261 169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
262 3-carboxamide).
263 170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
264 pentylindazole-3-carboxamide).
265 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
266 (4-fluorobenzyl)indazole-3-carboxamide).
267 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
268 1-pentylindazole-3-carboxamide).
269 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
270 yl)-1-(fluoropentyl)indole-3-carboxamide).
271 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
272 methoxybenzyl)]phenethylamine).
273 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
274 methoxybenzyl)]phenethylamine).
275 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
276 (cyclohexylmethyl)indazole-3-carboxamide).
277 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
278 carboxylate).
279 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
280 3-carboxamide).
281 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
282 (fluoropentyl)indazole-3-carboxamide).
283 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
284 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
285 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
286 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
287 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
288 hexahydrobenzo[c]chromen-1-ol).
289 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
290 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
291 hexahydrobenzo[c]chromen-1-ol).
292 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
293 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
294 diol).
295 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
296 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
297 tetrahydro-6aH-benzo[c]chromen-1-ol).
298 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
299 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
300 187. MAPB ((2-Methylaminopropyl)benzofuran).
301 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
302 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
303 190. Synthetic Cannabinoids.—Unless specifically excepted
304 or unless listed in another schedule or contained within a
305 pharmaceutical product approved by the United States Food and
306 Drug Administration, any material, compound, mixture, or
307 preparation that contains any quantity of a synthetic
308 cannabinoid found to be in any of the following chemical class
309 descriptions, or homologues, nitrogen-heterocyclic analogs,
310 isomers (including optical, positional, or geometric), esters,
311 ethers, salts, and salts of homologues, nitrogen-heterocyclic
312 analogs, isomers, esters, or ethers, whenever the existence of
313 such homologues, nitrogen-heterocyclic analogs, isomers, esters,
314 ethers, salts, and salts of isomers, esters, or ethers is
315 possible within the specific chemical class or designation.
316 Since nomenclature of these synthetically produced cannabinoids
317 is not internationally standardized and may continually evolve,
318 these structures or the compounds of these structures shall be
319 included under this subparagraph, regardless of their specific
320 numerical designation of atomic positions covered, if it can be
321 determined through a recognized method of scientific testing or
322 analysis that the substance contains properties that fit within
323 one or more of the following categories:
324 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
325 naturally contained in a plant of the genus Cannabis, the
326 synthetic equivalents of the substances contained in the plant
327 or in the resinous extracts of the genus Cannabis, or synthetic
328 substances, derivatives, and their isomers with similar chemical
329 structure and pharmacological activity, including, but not
330 limited to, Delta 9 tetrahydrocannabinols and their optical
331 isomers, Delta 8 tetrahydrocannabinols and their optical
332 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
333 isomers, or any compound containing a tetrahydrobenzo[c]chromene
334 structure with substitution at either or both the 3-position or
335 9-position, with or without substitution at the 1-position with
336 hydroxyl or alkoxy groups, including, but not limited to:
337 (I) Tetrahydrocannabinol.
338 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
339 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
340 ol).
341 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
342 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
343 ol).
344 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
345 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
346 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
347 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
348 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
349 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
350 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
351 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
352 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
353 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
354 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
355 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
356 (X) Parahexyl.
357 b. Naphthoylindoles, Naphthoylindazoles,
358 Naphthoylcarbazoles, Naphthylmethylindoles,
359 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
360 compound containing a naphthoylindole, naphthoylindazole,
361 naphthoylcarbazole, naphthylmethylindole,
362 naphthylmethylindazole, or naphthylmethylcarbazole structure,
363 with or without substitution on the indole, indazole, or
364 carbazole ring to any extent, whether or not substituted on the
365 naphthyl ring to any extent, including, but not limited to:
366 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
367 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
368 naphthoyl)indole).
369 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
370 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
371 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
372 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
373 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
374 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
375 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
376 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
377 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
378 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
379 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
380 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
381 naphthoyl)indole).
382 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
383 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
384 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
385 naphthoyl)indole).
386 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
387 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
388 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
389 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
390 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
391 naphthylmethyl]indole).
392 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
393 naphthoyl)indole).
394 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
395 naphthoyl)indole).
396 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
397 naphthoyl)indole).
398 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
399 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
400 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
401 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
402 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
403 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
404 naphthoyl)indole).
405 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
406 naphthoyl)indole).
407 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
408 naphthoyl)indole).
409 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
410 naphthoyl)indole).
411 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
412 naphthoyl)indole).
413 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
414 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
415 naphthoyl)indazole).
416 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
417 naphthoyl)indole).
418 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
419 naphthoyl)indole).
420 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
421 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
422 naphthoyl)carbazole).
423 c. Naphthoylpyrroles.—Any compound containing a
424 naphthoylpyrrole structure, with or without substitution on the
425 pyrrole ring to any extent, whether or not substituted on the
426 naphthyl ring to any extent, including, but not limited to:
427 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
428 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
429 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
430 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
431 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
432 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
433 naphthoyl)pyrrole).
434 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
435 naphthoyl)pyrrole).
436 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
437 naphthoyl)pyrrole).
438 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
439 naphthoyl)pyrrole).
440 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
441 naphthoyl)pyrrole).
442 d. Naphthylmethylenindenes.—Any compound containing a
443 naphthylmethylenindene structure, with or without substitution
444 at the 3-position of the indene ring to any extent, whether or
445 not substituted on the naphthyl ring to any extent, including,
446 but not limited to, JWH-176 (3-Pentyl-1
447 (naphthylmethylene)indene).
448 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
449 compound containing a phenylacetylindole or phenylacetylindazole
450 structure, with or without substitution on the indole or
451 indazole ring to any extent, whether or not substituted on the
452 phenyl ring to any extent, including, but not limited to:
453 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
454 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
455 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
456 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
457 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
458 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
459 (VII) Cannabipiperidiethanone.
460 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
461 methoxyphenylacetyl)indole).
462 f. Cyclohexylphenols.—Any compound containing a
463 cyclohexylphenol structure, with or without substitution at the
464 5-position of the phenolic ring to any extent, whether or not
465 substituted on the cyclohexyl ring to any extent, including, but
466 not limited to:
467 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
468 yl)phenol).
469 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
470 homologue).
471 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
472 methyloctan-2-yl)phenol).
473 g. Benzoylindoles and Benzoylindazoles.—Any compound
474 containing a benzoylindole or benzoylindazole structure, with or
475 without substitution on the indole or indazole ring to any
476 extent, whether or not substituted on the phenyl ring to any
477 extent, including, but not limited to:
478 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
479 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
480 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
481 iodo-5-nitrobenzoyl)indole).
482 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
483 methoxybenzoyl)indole).
484 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
485 iodobenzoyl)indole).
486 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
487 (VII) RCS-4 C4 homologue (1-Butyl-3-(4
488 methoxybenzoyl)indole).
489 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
490 3-(4-methoxybenzoyl)indole).
491 h. Tetramethylcyclopropanoylindoles and
492 Tetramethylcyclopropanoylindazoles.—Any compound containing a
493 tetramethylcyclopropanoylindole or
494 tetramethylcyclopropanoylindazole structure, with or without
495 substitution on the indole or indazole ring to any extent,
496 whether or not substituted on the tetramethylcyclopropyl group
497 to any extent, including, but not limited to:
498 (I) UR-144 (1-Pentyl-3-(2,2,3,3
499 tetramethylcyclopropanoyl)indole).
500 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
501 tetramethylcyclopropanoyl)indole).
502 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
503 tetramethylcyclopropanoyl)indole).
504 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
505 tetramethylcyclopropanoyl)indole).
506 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
507 tetramethylcyclopropanoyl)indole).
508 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
509 tetramethylcyclopropanoyl)indole).
510 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
511 tetramethylcyclopropanoyl)indole).
512 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
513 tetramethylcyclopropanoyl)indazole).
514 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
515 tetramethylcyclopropanoyl)indole).
516 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
517 tetramethylcyclopropanoyl)indole).
518 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
519 carboxamides, and Adamantylindazole carboxamides.—Any compound
520 containing an adamantoyl indole, adamantoyl indazole, adamantyl
521 indole carboxamide, or adamantyl indazole carboxamide structure,
522 with or without substitution on the indole or indazole ring to
523 any extent, whether or not substituted on the adamantyl ring to
524 any extent, including, but not limited to:
525 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
526 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
527 3-carboxamide).
528 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
529 carboxamide).
530 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
531 adamantoyl)indole).
532 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
533 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
534 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
535 adamantoyl)indole).
536 j. Quinolinylindolecarboxylates,
537 Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
538 and Quinolinylindazolecarboxamides.—Any compound containing a
539 quinolinylindole carboxylate, quinolinylindazole carboxylate,
540 isoquinolinylindole carboxylate, isoquinolinylindazole
541 carboxylate, quinolinylindole carboxamide, quinolinylindazole
542 carboxamide, isoquinolinylindole carboxamide, or
543 isoquinolinylindazole carboxamide structure, with or without
544 substitution on the indole or indazole ring to any extent,
545 whether or not substituted on the quinoline or isoquinoline ring
546 to any extent, including, but not limited to:
547 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
548 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
549 carboxylate).
550 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
551 carboxylate).
552 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
553 carboxylate).
554 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
555 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
556 3-carboxylate).
557 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
558 3-carboxylate).
559 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
560 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
561 carboxamide).
562 k. Naphthylindolecarboxylates and
563 Naphthylindazolecarboxylates.—Any compound containing a
564 naphthylindole carboxylate or naphthylindazole carboxylate
565 structure, with or without substitution on the indole or
566 indazole ring to any extent, whether or not substituted on the
567 naphthyl ring to any extent, including, but not limited to:
568 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
569 carboxylate).
570 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
571 carboxylate).
572 (III) Fluoro SDB-005 (1-Naphthalenyl 1
573 (fluoropentyl)indazole-3-carboxylate).
574 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
575 carboxylate).
576 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
577 carboxylate).
578 l. Naphthylindole carboxamides and Naphthylindazole
579 carboxamides.—Any compound containing a naphthylindole
580 carboxamide or naphthylindazole carboxamide structure, with or
581 without substitution on the indole or indazole ring to any
582 extent, whether or not substituted on the naphthyl ring to any
583 extent, including, but not limited to:
584 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
585 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
586 3-carboxamide).
587 (III) Chloro-NNEI (N-Naphthalen-1-yl 1
588 (chloropentyl)indole-3-carboxamide).
589 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
590 carboxamide).
591 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
592 (fluoropentyl)indazole-3-carboxamide).
593 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
594 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
595 Alkylcarbonyl indazole carboxylates.—Any compound containing an
596 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
597 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
598 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
599 indole carboxamide, indazole carboxamide, indole carboxylate, or
600 indazole carboxylate, with or without substitution on the indole
601 or indazole ring to any extent, whether or not substituted on
602 the alkylcarbonyl group to any extent, including, but not
603 limited to:
604 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
605 pentylindole-3-carboxamide).
606 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
607 yl)-1-(fluoropentyl)indole-3-carboxamide).
608 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
609 (fluoropentyl)indole-3-carboxamide).
610 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
611 pentylindazole-3-carboxamide).
612 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
613 1-(fluoropentyl)indazole-3-carboxamide).
614 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
615 1-pentylindazole-3-carboxamide).
616 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
617 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
618 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
619 (4-fluorobenzyl)indazole-3-carboxamide).
620 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
621 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
622 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
623 (cyclohexylmethyl)indazole-3-carboxamide).
624 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
625 (cyclohexylmethyl)indazole-3-carboxamide).
626 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
627 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
628 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
629 pentylindazole-3-carboxamide).
630 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
631 (fluoropentyl)indazole-3-carboxamide).
632 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
633 fluorobenzyl)indazole-3-carboxamide).
634 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
635 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
636 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
637 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
638 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
639 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
640 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
641 fluoropentyl)indole-3-carboxamide).
642 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
643 fluoropentyl)indazole-3-carboxamide).
644 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
645 (cyclohexylmethyl)indazole-3-carboxamide).
646 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
647 fluorobenzyl)indazole-3-carboxamide).
648 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
649 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
650 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
651 Any compound containing a N-(2-phenylpropan-2-yl) indole
652 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
653 structure, with or without substitution on the indole or
654 indazole ring to any extent, whether or not substituted on the
655 phenyl ring of the cumyl group to any extent, including, but not
656 limited to:
657 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
658 carboxamide).
659 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
660 (fluoropentyl)indole-3-carboxamide).
661 o. Other Synthetic Cannabinoids.—Any material, compound,
662 mixture, or preparation that contains any quantity of a
663 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
664 (I) With or without modification or replacement of a
665 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
666 between either two core rings, or linkage between a core ring
667 and group structure, with or without the addition of a carbon or
668 replacement of a carbon;
669 (II) With or without replacement of a core ring or group
670 structure, whether or not substituted on the ring or group
671 structures to any extent; and
672 (III) Is a cannabinoid receptor agonist, unless
673 specifically excepted or unless listed in another schedule or
674 contained within a pharmaceutical product approved by the United
675 States Food and Drug Administration.
676 191. Substituted Cathinones.—Unless specifically excepted,
677 listed in another schedule, or contained within a pharmaceutical
678 product approved by the United States Food and Drug
679 Administration, any material, compound, mixture, or preparation,
680 including its salts, isomers, esters, or ethers, and salts of
681 isomers, esters, or ethers, whenever the existence of such salts
682 is possible within any of the following specific chemical
683 designations:
684 a. Any compound containing a 2-amino-1-phenyl-1-propanone
685 structure;
686 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
687 structure; or
688 c. Any compound containing a 2-amino-1-thiophenyl-1
689 propanone structure,
690
691 whether or not the compound is further modified:
692 (I) With or without substitution on the ring system to any
693 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
694 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
695 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
696 substituents;
697 (II) With or without substitution at the 3-propanone
698 position with an alkyl substituent or removal of the methyl
699 group at the 3-propanone position;
700 (III) With or without substitution at the 2-amino nitrogen
701 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
702 not further substituted in the ring system; or
703 (IV) With or without inclusion of the 2-amino nitrogen atom
704 in a cyclic structure, including, but not limited to:
705 (A) Methcathinone.
706 (B) Ethcathinone.
707 (C) Methylone (3,4-Methylenedioxymethcathinone).
708 (D) 2,3-Methylenedioxymethcathinone.
709 (E) MDPV (3,4-Methylenedioxypyrovalerone).
710 (F) Methylmethcathinone.
711 (G) Methoxymethcathinone.
712 (H) Fluoromethcathinone.
713 (I) Methylethcathinone.
714 (J) Butylone (3,4-Methylenedioxy-alpha
715 methylaminobutyrophenone).
716 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
717 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
718 (M) Naphyrone (Naphthylpyrovalerone).
719 (N) Bromomethcathinone.
720 (O) Buphedrone (alpha-Methylaminobutyrophenone).
721 (P) Eutylone (3,4-Methylenedioxy-alpha
722 ethylaminobutyrophenone).
723 (Q) Dimethylcathinone.
724 (R) Dimethylmethcathinone.
725 (S) Pentylone (3,4-Methylenedioxy-alpha
726 methylaminovalerophenone).
727 (T) Pentedrone (alpha-Methylaminovalerophenone).
728 (U) MDPPP (3,4-Methylenedioxy-alpha
729 pyrrolidinopropiophenone).
730 (V) MDPBP (3,4-Methylenedioxy-alpha
731 pyrrolidinobutyrophenone).
732 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
733 (X) PPP (Pyrrolidinopropiophenone).
734 (Y) PVP (Pyrrolidinovalerophenone) or
735 (Pyrrolidinopentiophenone).
736 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
737 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
738 (BB) F-MABP (Fluoromethylaminobutyrophenone).
739 (CC) Me-EABP (Methylethylaminobutyrophenone).
740 (DD) PBP (Pyrrolidinobutyrophenone).
741 (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
742 (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
743 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
744 (HH) Dimethylone (3,4-Methylenedioxy-N,N
745 dimethylcathinone).
746 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
747 (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
748 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
749 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
750 (MM) Methylbuphedrone (Methyl-alpha
751 methylaminobutyrophenone).
752 (NN) Methyl-alpha-methylaminohexanophenone.
753 (OO) N-Ethyl-N-methylcathinone.
754 (PP) PHP (Pyrrolidinohexanophenone).
755 (QQ) PV8 (Pyrrolidinoheptanophenone).
756 (RR) Chloromethcathinone.
757 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
758 192. Substituted Phenethylamines.—Unless specifically
759 excepted or unless listed in another schedule, or contained
760 within a pharmaceutical product approved by the United States
761 Food and Drug Administration, any material, compound, mixture,
762 or preparation, including its salts, isomers, esters, or ethers,
763 and salts of isomers, esters, or ethers, whenever the existence
764 of such salts is possible within any of the following specific
765 chemical designations, any compound containing a phenethylamine
766 structure, without a beta-keto group, and without a benzyl group
767 attached to the amine group, whether or not the compound is
768 further modified with or without substitution on the phenyl ring
769 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
770 halide, fused alkylenedioxy, fused furan, fused benzofuran,
771 fused dihydrofuran, or fused tetrahydropyran substituents,
772 whether or not further substituted on a ring to any extent, with
773 or without substitution at the alpha or beta position by any
774 alkyl substituent, with or without substitution at the nitrogen
775 atom, and with or without inclusion of the 2-amino nitrogen atom
776 in a cyclic structure, including, but not limited to:
777 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
778 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
779 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
780 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
781 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
782 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
783 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
784 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
785 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
786 j. 2C-H (2,5-Dimethoxyphenethylamine).
787 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
788 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
789 m. MDMA (3,4-Methylenedioxymethamphetamine).
790 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
791 Methylenedioxy-N-methylbutanamine).
792 o. MDA (3,4-Methylenedioxyamphetamine).
793 p. 2,5-Dimethoxyamphetamine.
794 q. Fluoroamphetamine.
795 r. Fluoromethamphetamine.
796 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
797 t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
798 u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
799 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
800 w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
801 x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
802 y. PMA (4-Methoxyamphetamine).
803 z. N-Ethylamphetamine.
804 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
805 bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
806 cc. PMMA (4-Methoxymethamphetamine).
807 dd. N,N-Dimethylamphetamine.
808 ee. 3,4,5-Trimethoxyamphetamine.
809 ff. 4-APB (4-(2-Aminopropyl)benzofuran).
810 gg. 5-APB (5-(2-Aminopropyl)benzofuran).
811 hh. 6-APB (6-(2-Aminopropyl)benzofuran).
812 ii. 7-APB (7-(2-Aminopropyl)benzofuran).
813 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
814 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
815 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
816 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
817 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
818 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
819 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
820 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
821 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
822 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
823 dihydrobenzofuran),
824
825 which does not include phenethylamine, mescaline as described in
826 subparagraph 20., substituted cathinones as described in
827 subparagraph 191., N-Benzyl phenethylamine compounds as
828 described in subparagraph 193., or methamphetamine as described
829 in subparagraph (2)(c)5.
830 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
831 excepted or unless listed in another schedule, or contained
832 within a pharmaceutical product approved by the United States
833 Food and Drug Administration, any material, compound, mixture,
834 or preparation, including its salts, isomers, esters, or ethers,
835 and salts of isomers, esters, or ethers, whenever the existence
836 of such salts is possible within any of the following specific
837 chemical designations, any compound containing a phenethylamine
838 structure without a beta-keto group, with substitution on the
839 nitrogen atom of the amino group with a benzyl substituent, with
840 or without substitution on the phenyl or benzyl ring to any
841 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
842 alkylenedioxy, fused furan, fused benzofuran, or fused
843 tetrahydropyran substituents, whether or not further substituted
844 on a ring to any extent, with or without substitution at the
845 alpha position by any alkyl substituent, including, but not
846 limited to:
847 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
848 methoxybenzyl)]phenethylamine).
849 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
850 hydroxybenzyl)]phenethylamine).
851 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
852 fluorobenzyl)]phenethylamine).
853 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
854 methylenedioxybenzyl)]phenethylamine).
855 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
856 methoxybenzyl)]phenethylamine).
857 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
858 hydroxybenzyl)]phenethylamine).
859 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
860 fluorobenzyl)]phenethylamine).
861 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
862 methylenedioxybenzyl)]phenethylamine).
863 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
864 methoxybenzyl)]phenethylamine).
865 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
866 methoxybenzyl)]phenethylamine).
867 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
868 methoxybenzyl)]phenethylamine).
869 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
870 methoxybenzyl)]phenethylamine).
871 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
872 hydroxybenzyl)]phenethylamine).
873 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
874 fluorobenzyl)]phenethylamine).
875 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
876 methylenedioxybenzyl)]phenethylamine).
877 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
878 methoxybenzyl)]phenethylamine).
879 q. 25H-NBOH (2,5-Dimethoxy-[N-(2
880 hydroxybenzyl)]phenethylamine).
881 r. 25H-NBF (2,5-Dimethoxy-[N-(2
882 fluorobenzyl)]phenethylamine).
883 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
884 methoxybenzyl)]phenethylamine),
885
886 which does not include substituted cathinones as described in
887 subparagraph 191.
888 194. Substituted Tryptamines.—Unless specifically excepted
889 or unless listed in another schedule, or contained within a
890 pharmaceutical product approved by the United States Food and
891 Drug Administration, any material, compound, mixture, or
892 preparation containing a 2-(1H-indol-3-yl)ethanamine, for
893 example tryptamine, structure with or without mono- or di
894 substitution of the amine nitrogen with alkyl or alkenyl groups,
895 or by inclusion of the amino nitrogen atom in a cyclic
896 structure, whether or not substituted at the alpha position with
897 an alkyl group, whether or not substituted on the indole ring to
898 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
899 groups, including, but not limited to:
900 a. Alpha-Ethyltryptamine.
901 b. Bufotenine.
902 c. DET (Diethyltryptamine).
903 d. DMT (Dimethyltryptamine).
904 e. MET (N-Methyl-N-ethyltryptamine).
905 f. DALT (N,N-Diallyltryptamine).
906 g. EiPT (N-Ethyl-N-isopropyltryptamine).
907 h. MiPT (N-Methyl-N-isopropyltryptamine).
908 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
909 j. 5-Hydroxy-N-methyltryptamine.
910 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
911 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
912 m. Methyltryptamine.
913 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
914 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
915 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
916 q. DiPT (N,N-Diisopropyltryptamine).
917 r. DPT (N,N-Dipropyltryptamine).
918 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
919 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
920 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
921 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
922 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
923 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
924 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
925 isopropyltryptamine).
926 z. Methyl-alpha-ethyltryptamine.
927 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
928
929 which does not include tryptamine, psilocyn as described in
930 subparagraph 34., or psilocybin as described in subparagraph 33.
931 195. Substituted Phenylcyclohexylamines.—Unless
932 specifically excepted or unless listed in another schedule, or
933 contained within a pharmaceutical product approved by the United
934 States Food and Drug Administration, any material, compound,
935 mixture, or preparation containing a phenylcyclohexylamine
936 structure, with or without any substitution on the phenyl ring,
937 any substitution on the cyclohexyl ring, any replacement of the
938 phenyl ring with a thiophenyl or benzothiophenyl ring, with or
939 without substitution on the amine with alkyl, dialkyl, or alkoxy
940 substituents, inclusion of the nitrogen in a cyclic structure,
941 or any combination of the above, including, but not limited to:
942 a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
943 (Benocyclidine).
944 b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
945 of phencyclidine).
946 c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
947 analog of phencyclidine).
948 d. PCPr (Phenylcyclohexylpropylamine).
949 e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
950 analog of phencyclidine).
951 f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
952 g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
953 h. Methoxetamine.
954 i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
955 j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
956 k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
957 l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
958 m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
959 n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
960 o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
961 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
962 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
963 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
964 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2
965 piperidinylidene]-benzenesulfonamide.
966 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2
967 piperidinylidene]-benzenesulfonamide.
968 198. AH-7921, 3,4-dichloro-N-[[1
969 (dimethylamino)cyclohexyl]methyl]-benzamide.
970 199. U47700, trans-3,4-dichloro-N-[2
971 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
972 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
973 dihydrochloride.
974 Section 2. This act shall take effect upon becoming a law.
